BDTX-1535: A MasterKey EGFR inhibitor targeting classical and non-classical oncogenic driver mutations and the C797S acquired resistance mutation to address the evolving molecular landscape of EGFR mutant NSCLC

Tagrisso (osimertinib) - AstraZeneca

silevertinib (BDTX-1535) - Black Diamond Therap

E. Dardenne 1; M. O'Connor 1; M. Nilsson 2; J. He 2; X. Yu 2; J. V. Heymach 2; X. Le 2; E. Buck1

Mar 6, 2024